Safety
Solicited AEs at the injection site were reported more frequently in the vaccine group than the placebo group after the first dose (7269 [38.2%] vs 737 [15.5%]), second dose (6470 [35.7%] vs 649 [14.4%]), and third dose (1042 [25.0%] vs 98 [9.3%]) (